Presentation is loading. Please wait.

Presentation is loading. Please wait.

Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: A randomized, double-blind clinical trial  Michael Weschta, MD, Dagmar Rimek,

Published byViktor Vlček Modified over 5 years ago

Similar presentations

Presentation on theme: "Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: A randomized, double-blind clinical trial  Michael Weschta, MD, Dagmar Rimek,"— Presentation transcript:

1 Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: A randomized, double-blind clinical trial  Michael Weschta, MD, Dagmar Rimek, MD, Marc Formanek, Doreen Polzehl, MD, Andreas Podbielski, MD, PhD, Herbert Riechelmann, MD, PhD  Journal of Allergy and Clinical Immunology  Volume 113, Issue 6, Pages (June 2004) DOI: /j.jaci Copyright © 2004 American Academy of Allergy, Asthma and Immunology Terms and Conditions

2 Fig 1 Study design. A pretest-posttest double blind control group design was used. Patients were randomly allocated to the 2 treatment arms in this study. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2004 American Academy of Allergy, Asthma and Immunology Terms and Conditions

3 Fig 2 CT scores (line in box, median; box, interquartile range; whiskers, lower and upper extremes) before and after 8 weeks of treatment with saline (control) or AMB nasal spray. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2004 American Academy of Allergy, Asthma and Immunology Terms and Conditions

4 Fig 3 Symptom scores (line in box, median; box, interquartile range; whiskers, highest and lowest values excluding outliers; asterisks, outliers) before and after 8 weeks of treatment with saline (control) or AMB nasal spray. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2004 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Download ppt "Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: A randomized, double-blind clinical trial  Michael Weschta, MD, Dagmar Rimek,"

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Alveolar nitric oxide and asthma control in mild untreated asthma

Alveolar nitric oxide and asthma control in mild untreated asthma
Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.

Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.
Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: A longitudinal analysis  Rafael Pasternack, MD, PhD, Heini Huhtala, MSc, Jussi Karjalainen,

Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: A longitudinal analysis  Rafael Pasternack, MD, PhD, Heini Huhtala, MSc, Jussi Karjalainen,
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.
Chronic rhinosinusitis: Potential new use for topical sulfasalazine

Chronic rhinosinusitis: Potential new use for topical sulfasalazine
Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.
Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Desensitization to Chemotherapeutic Agents

Desensitization to Chemotherapeutic Agents
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
John W. Steinke, PhD, Spencer C. Payne, MD, M

John W. Steinke, PhD, Spencer C. Payne, MD, M

Similar presentations

Ads by Google